Wed, Oct 22, 2014, 1:42 AM EDT - U.S. Markets open in 7 hrs 48 mins


% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

frobinso1 17 posts  |  Last Activity: Oct 16, 2014 10:17 AM Member since: May 4, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Placebo used

    by davidssaville Oct 16, 2014 2:16 AM
    frobinso1 frobinso1 Oct 16, 2014 10:17 AM Flag

    Based on results so far the placebo use was PBT2 (he he). We must maintain a sense of humor to keep our sanity.

  • frobinso1 frobinso1 Oct 15, 2014 5:33 PM Flag

    He made this statement in reply to question number 2

  • frobinso1 frobinso1 Oct 15, 2014 5:33 PM Flag

    I see on the slide listing B-Amyloid (Anti-Abeta Therapies) it lists GSMs, Immune, PBT2

    As he just now mentions PBT2 again in talking of "targeting metals is as good a strategy as ANY out there"!!!


  • Reply to

    Navidea got ALL ACES today

    by quantsbank Oct 15, 2014 1:41 PM
    frobinso1 frobinso1 Oct 15, 2014 2:43 PM Flag

    I have been sucking wind on this stock for along time, but added more today. Good news fed into a bad market is ok by me. Nice to get an opportunity to buy more before this news sinks in. I like the options incentives in tranches requiring a 2.50 & 3.50 shareprice. That is how companies should always do it, but most just give away options to execs anymore without requiring shareprice performance. This is truly how it should always be done. Now I know the CEO will be working hard to make things happen, and he appears to have the experience to get it done.

  • Reply to

    Metals Theory and PBT2

    by interestingtome Oct 10, 2014 10:45 AM
    frobinso1 frobinso1 Oct 10, 2014 1:48 PM Flag

    It's obvious you are back here to make up your tremendous losses on the two stocks you were pumping - Mankind and EDAP, both of which completely tanked. If you think you have any credibility whatsoever on this board, think again.

    Maybe you can buy into Pran and recoup some of your losses.

    Go read the normal aged mouse study results, and the findings show are quite promising for PBT2 and HD.

  • frobinso1 frobinso1 Oct 7, 2014 2:01 PM Flag

    The aforementioned result is from the normal aged mouse study - not ZNT3 knock-out AD might be different w/AD...

  • frobinso1 frobinso1 Oct 7, 2014 1:51 PM Flag

    Here it is...glad they are doing further research...
    I found the mention I was thinking of in this excerpt from the normal aged mouse study in aging cell:

    PBT2 increases VGLUT1 and glutamate levels

    Whether the increase in cellular zinc levels directly translates to an increased availability of zinc specifically at the synapse is unclear. To this end, we examined the levels of the zinc transporter 3 (ZnT3) protein in the hippocampus. ZnT3 is primarily localized to glutamatergic synapses (Palmiter et al., 1996) and is essential for loading zinc into synaptic vesicles (Cole et al., 1999). We have previously shown that the ablation of ZnT3 results in a profound age-dependent cognitive phenotype and that there is an age-related decline in this protein in both normal mice and healthy older adults and a further exaggerated decline in AD (Adlard et al., 2010). Thus, in addition to an increase in zinc levels, a plausible mechanistic pathway to account for the restored cognitive function following PBT2 treatment observed in this study would require an upregulation of a synaptic vesicle zinc transporter such as ZnT3 (PBT2 itself may also be acting as a surrogate vesicular/synaptic zinc transporter, which is the subject of ongoing investigations). This would ensure the correct localization of zinc that would then facilitate the cellular signalling pathways required for cognition. Surprisingly however, there was a significant decrease in total hippocampal ZnT3 levels following PBT2 treatment [PBT2 (−33%), P = 0.01] (Fig. 4a), suggesting that another zinc transporter may be activated following PBT2 treatment. Thus, we examined the levels of the vesicular glutamate transporter 1 (VGLUT1) in the hippocampus

  • frobinso1 frobinso1 Oct 7, 2014 1:46 PM Flag

    I am pretty sure that an early Adlard paper conjectured that znt3 was an anticipated MOA of PBT2, but that later evidence suggested otherwise in one study. I'll search and come back with the reference. Was PBT2 mentioned at all in this study?

  • Reply to


    by esoteric687 Aug 28, 2014 11:37 AM
    frobinso1 frobinso1 Aug 28, 2014 3:02 PM Flag

    rk, last year with this annual reporting they also diluted on 8/30/2013. It's my main concern. Wish I knew the answer. I don't know whether to expect a pop or drop.

  • Reply to

    Could go either way.

    by toxxxicsludge Aug 5, 2014 12:44 PM
    frobinso1 frobinso1 Aug 5, 2014 3:08 PM Flag

    I would expect higher volumes for sure if it drops below 2:00.

  • Reply to

    Could go either way.

    by toxxxicsludge Aug 5, 2014 12:44 PM
    frobinso1 frobinso1 Aug 5, 2014 3:06 PM Flag

    I haven't reloaded yet. Still sucking wind on MNKD. I'm not a technician, but moodwise unless there is a catalyst I don't see why it couldn't go into prior range where one could reload in the high 1.60s low 1.70s again. The rise was pretty much on no news. Then we received finally an update on the AD trial, and it helped, but did not resurrect likelihood of PBT2 obtaining accelerated approval for AD, and lacking cognitive improvement - reduced atrophy might be a path, but only if accepted someday as a surrogate measure and I don't hear any talk of that coming from the FDA at this point in time.

    I still think there are potential catalysts that would take us much, much higher. Such a catalyst could come at any time. It's just whether something like that will come along at the right time is a crapshoot.

    My hopes for the open label extension to possibly resurrect hope for PBT2s accelerated approval for AD, in addition to additional progress toward PBT2 for HD. HD is a rare disease. One possibility is that if PBT2 is only approved for HD, the pricing could be substantially higher in accordance with industry practice.

  • frobinso1 frobinso1 Aug 3, 2014 10:35 PM Flag

    Glad to see Finkelstein's as having work paid for by Prana.

  • frobinso1 frobinso1 Jul 23, 2014 4:49 PM Flag

    When previously upon issue of new significant patents a news release comes out next day, but this time silence it adds to the notion they are in a quiet period. However, it could be entirely earnings related at this point in time.

  • Reply to

    Patent for technosphere

    by sparrowjeb Jul 23, 2014 11:44 AM
    frobinso1 frobinso1 Jul 23, 2014 12:15 PM Flag

    So the only other explanation if a news release doesn't come out is that they are in a quiet period due to partnership or buyout announcement.....
    Let's see...insiders taken care of....loaded up
    Debtor Deerfield taken care for max pain & gain when shorts said he didn't have another 40Mill
    I believe that means shareholder's next....I'm ready
    Bring it on

  • Reply to

    Patent for technosphere

    by sparrowjeb Jul 23, 2014 11:44 AM
    frobinso1 frobinso1 Jul 23, 2014 12:13 PM Flag

    In this example it took a day:
    MannKind Corporation Announces Issuance of Two Key U.S. Patents

    VALENCIA, Calif., Feb. 8 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Patent and Trademark Office has awarded the company two key patents relating to a method for inducing a cytotoxic T cell (CTL) response that will be utilized with the company's cancer immunotherapy products. MannKind is in late stage preclinical testing of therapeutic vaccines for treatment of colorectal, renal, ovarian, pancreatic and breast cancers. The company believes these vaccines will likely improve outcomes for a substantial portion of patients suffering from these cancers.

    U.S. Patent 6,994,851, issued yesterday, claims methods of obtaining a sustained CTL response by delivery of antigen to the lymphatic system, particularly intranodally, and maintaining the antigen in the lymphatic system over time. The method allows for the prolongation of the effector phase of the CTL response and can be applied to the treatment of cancer and chronic infections.

    U.S. Patent 6,977,074, issued December 20, 2005, claims methods of inducing a CTL response by delivering antigen directly to a lymph node or lymph vessel. Direct intralymphatic administration enables more efficient induction of CTL responses than can generally be obtained using more conventional routes of administration with any amount of antigen. This can be particularly advantageous when using DNA vaccines or small peptides to provide antigen.

    David Diamond, Director of Intellectual Property for MannKind Corporation, commented, "The issuance of these patents provides a strong proprietary foundation for our cancer immunotherapy program. Intralymphatic delivery greatly increases the number of CTL's against the cancer cells, wherever they may be in the body. In this way the body's natural immune system destroys the cancer without harm to normal cells and should improve efficacy and safety without ...

  • frobinso1 frobinso1 Jul 22, 2014 8:40 PM Flag

    Nice the we cater to the preppers in this day and age. Sweet! It may soon comprise most of the population. Definitely a blockbuster drug...

  • frobinso1 frobinso1 Jul 22, 2014 1:43 PM Flag

    What we have is proof that those shorts that were spouting that Deerfield did not have another 40 Million to loan were proven wrong, and the strength of MNKDs negotiation position just got $40 Million stronger.

1.970.00(0.00%)Oct 21 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.